Neurocrine Biosciences (NBIX) Change in Accured Expenses (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Change in Accured Expenses for 17 consecutive years, with -$8.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Accured Expenses fell 156.29% year-over-year to -$8.5 million; the trailing twelve-month figure through Jun 2026 stood at $125.3 million (down 6.21% YoY), and the FY2025 full-year result was $160.2 million, up 269.12% from the prior year.
• Change in Accured Expenses grew to -$8.5 million in Q2 2026 per NBIX's latest filing, from -$14.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $124.4 million in Q3 2023 and bottomed at -$98.3 million in Q4 2023.
• Historically, Change in Accured Expenses has averaged $19.1 million across 5 years, with a median of $15.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses soared 279.27% in 2023, then sank 467.28% in 2024.
• Over 5 years, Change in Accured Expenses stood at $37.6 million in 2022, then plunged by 361.44% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then slipped by 1.03% to $76.5 million in 2025, then tumbled by 111.11% to -$8.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$8.5 million, -$14.3 million, and $76.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.